[go: up one dir, main page]

SG11202005799XA - DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS - Google Patents

DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Info

Publication number
SG11202005799XA
SG11202005799XA SG11202005799XA SG11202005799XA SG11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA SG 11202005799X A SG11202005799X A SG 11202005799XA
Authority
SG
Singapore
Prior art keywords
fused ring
ring compounds
diaryl substituted
c5ar inhibitors
c5ar
Prior art date
Application number
SG11202005799XA
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Rajinder Singh
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of SG11202005799XA publication Critical patent/SG11202005799XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202005799XA 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS SG11202005799XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762609844P 2017-12-22 2017-12-22
PCT/US2018/066677 WO2019126431A1 (en) 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Publications (1)

Publication Number Publication Date
SG11202005799XA true SG11202005799XA (en) 2020-07-29

Family

ID=66950014

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005799XA SG11202005799XA (en) 2017-12-22 2018-12-20 DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS

Country Status (14)

Country Link
US (2) US10759807B2 (en)
EP (1) EP3728202A4 (en)
JP (1) JP7253557B2 (en)
KR (1) KR102852027B1 (en)
CN (1) CN111788184B (en)
AU (1) AU2018388657C1 (en)
BR (1) BR112020012374A2 (en)
CA (1) CA3086111A1 (en)
IL (1) IL275516B2 (en)
MA (1) MA51327A (en)
MX (1) MX2020006460A (en)
SG (1) SG11202005799XA (en)
TW (1) TWI817968B (en)
WO (1) WO2019126431A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630775B1 (en) 2017-05-31 2022-12-14 ChemoCentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
CN111406051A (en) 2017-09-03 2020-07-10 安吉昂生物医药公司 Vinylheterocycles as RHO-associated coiled coil kinase (ROCK) inhibitors
US10759807B2 (en) 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
EP3728203B1 (en) 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
KR20230031981A (en) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 Methods and compositions for preventing type 1 diabetes
CN112300169B (en) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 Pyrrolopyrazole derivatives, their preparation method and their application in medicine
EP4005638A4 (en) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
MX2022006439A (en) 2019-12-19 2022-07-19 Active Biotech Ab COMPOUNDS FOR THE TREATMENT OF EYE DISEASES ASSOCIATED WITH EXCESSIVE VASCULARIZATION.
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
EP4146191A1 (en) * 2020-05-06 2023-03-15 Dimerix Bioscience Pty Ltd Treatment for acute respiratory distress syndrome
CA3175602A1 (en) * 2020-05-07 2021-11-11 Jerome Molette Novel compounds for diagnosis
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
EP4237411A4 (en) 2020-10-28 2024-08-14 ChemoCentryx, Inc. METHODS OF TREATMENT OF HIDRADENITIS SUPPURATUM
EP4262800A4 (en) * 2020-12-21 2024-11-20 ChemoCentryx, Inc. TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR
KR102815351B1 (en) * 2022-04-20 2025-05-29 국립목포대학교산학협력단 Composition for preventing and treating valve calcification

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE60143041D1 (en) * 2000-08-10 2010-10-21 Pfizer Italia Srl Bicyclic pyrazoles are effective as kinase inhibitors, processes for their preparation, and pharmaceutical compositions containing them
EP1322309B1 (en) 2000-09-29 2008-08-13 Neurogen Corporation High affinity small molecule c5a receptor modulators
SE524438C2 (en) 2000-10-05 2004-08-10 Magnus Georg Goertz Remote controlled door-related locking arrangement, first and second computer program products, carrying medium and a computer-soluble medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
WO2003008829A1 (en) 2001-07-19 2003-01-30 Luk Lamellen Und Kupplungsbau Beteiligungs Kg Disengaging system having a parking blocking function for controlling a clutch
ITMI20012025A1 (en) 2001-09-28 2003-03-28 Dompe Spa QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as c5a receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
EP1534680B1 (en) 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) * 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0320020D0 (en) * 2003-08-27 2003-10-01 Mw Encap Ltd Improved formulation for providing an enteric coating material
CN101318962A (en) * 2003-09-17 2008-12-10 詹森药业有限公司 Fused heterocyclic compound
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
US20080119457A1 (en) * 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
EP2296475A4 (en) 2008-06-20 2014-03-05 Genentech Inc Triazolopyridine jak inhibitor compounds and methods
LT3508477T (en) 2008-12-22 2022-02-10 Chemocentryx, Inc. C5AR ANTAGONISTS
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SI2585064T1 (en) 2010-06-24 2017-08-31 Chemocentryx, Inc. C5ar antagonists
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
AU2013302473B2 (en) * 2012-08-16 2017-08-10 Janssen Pharmaceutica Nv Pyrrolopyrazoles as N-type calcium channel blockers
CN103421006B (en) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-tetra-substituted dihydro pyrazol hexahydropyridine derivant and its preparation method and application
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
EP3630775B1 (en) 2017-05-31 2022-12-14 ChemoCentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
US10759807B2 (en) 2017-12-22 2020-09-01 Chemocentryx, Inc. Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
EP3728203B1 (en) 2017-12-22 2024-03-13 ChemoCentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists

Also Published As

Publication number Publication date
TWI817968B (en) 2023-10-11
KR102852027B1 (en) 2025-08-27
JP2021506900A (en) 2021-02-22
EP3728202A4 (en) 2021-05-26
AU2018388657C1 (en) 2023-03-23
RU2020124094A (en) 2022-01-24
KR20200110656A (en) 2020-09-24
AU2018388657A1 (en) 2020-07-09
IL275516A (en) 2020-08-31
US11485737B2 (en) 2022-11-01
TW201934552A (en) 2019-09-01
AU2018388657B2 (en) 2022-12-01
WO2019126431A1 (en) 2019-06-27
CA3086111A1 (en) 2019-06-27
US20210009596A1 (en) 2021-01-14
BR112020012374A2 (en) 2020-11-24
IL275516B2 (en) 2023-12-01
NZ765590A (en) 2024-01-26
US20190194208A1 (en) 2019-06-27
CN111788184A (en) 2020-10-16
JP7253557B2 (en) 2023-04-06
MA51327A (en) 2021-05-26
CN111788184B (en) 2023-12-22
IL275516B1 (en) 2023-08-01
MX2020006460A (en) 2020-11-06
EP3728202A1 (en) 2020-10-28
US10759807B2 (en) 2020-09-01

Similar Documents

Publication Publication Date Title
IL275516A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
IL275500A (en) Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors
SG11202104326TA (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
IL264092A (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
WO2016044463A3 (en) Mk2 inhibitors and uses thereof
SG11202000532SA (en) Compounds, compositions and methods
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
PL3676297T3 (en) Compounds, compositions and methods
SI3397631T1 (en) Substituted 3-azabicyclo(3.1.0)hexanes as ketohexokinase inhibitors
EP3160940A4 (en) Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
IL271399A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL251775B (en) Substituted 2, 4-diamino quinoline compounds, compositions comprising same and uses thereof
IL270505B1 (en) Compounds, compositions and methods
IL278262A (en) Oxo-substituted compound
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
IL282905A (en) Cycloalkane-1,3-diamine derivative
IL259556A (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
PL3515454T3 (en) Crystalline polymorphic form of 3-hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2lambda5-[1,2]oxaphosphinane
PL3589637T3 (en) Compounds useful for inhibiting ror-gamma-t
HK40040511A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
MX2016017019A (en) Method for preparation of 4-alkoxy-1,1,1-trifluorobut-3-en-2- ones from 1,1,1-trifluoroacetone.
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
PL3589638T3 (en) Compounds useful for inhibiting ror-gamma-t
GB201714439D0 (en) Organic intermediate 1,6-cyclohexanedione synthesis method
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof